Lumosa Therapeutics , Ltd. (6535.TWO) has a profit margin of -1236.28%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
Lumosa Therapeutics , Ltd. (6535.TWO) currently reports a profit margin of -1236.28% as of September 2026. That compares with -1017.7% in the prior-year period — down 21.5% year over year. That is below the Healthcare sector average of 17.63%. Use the charts on this page to explore Lumosa Therapeutics , Ltd.'s profit margin history and peer comparisons.
Lumosa Therapeutics , Ltd.'s profit margin decreased from -1017.7% to -1236.28% — a 21.5% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Lumosa Therapeutics , Ltd.'s profit margin of -1236.28% is lower than the Healthcare sector average of 17.63%. That is roughly 7113.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Lumosa Therapeutics , Ltd.'s current -1236.28% should be judged against Healthcare norms (sector average: 17.63%) and against 6535.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -1236.28%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 17.63%. From there, open related valuation or income-statement pages for Lumosa Therapeutics , Ltd., and consider following 6535.TWO for alerts when major investors trade the stock.